How Cancer immunotherapy Works

Cancer cells try to hide from the immune system by looking similar to normal cells, but they display unique molecular markers called tumor-associated antigens on their surfaces. These antigens act like fingerprints that distinguish cancer cells from healthy tissue. Immunotherapy treatments can train immune cells—particularly T cells—to recognize these specific markers, much like teaching a search dog to identify a particular scent.

Some immunotherapies use cancer vaccines that expose the immune system to these cancer-specific antigens in a controlled way, helping T cells memorize what to look for. Other approaches involve removing a patient's T cells, genetically engineering them in the lab to recognize particular cancer markers (called CAR-T cell therapy), then infusing them back into the body. Once trained, these immune cells can scan the body and identify cancer cells among billions of healthy cells.

The recognition step is crucial because the immune system must distinguish friend from foe with precision. If recognition is too broad, the immune system might attack healthy tissue, causing autoimmune problems. If it's too narrow, cancer cells can escape detection by slightly altering their surface markers—which is why targeting multiple antigens often works better than focusing on just one.

Cancer cells have evolved a devious trick: they express proteins like PD-L1 on their surface that bind to checkpoint receptors (like PD-1 or CTLA-4) on T cells, essentially sending "stand down" signals. These checkpoints normally exist to prevent the immune system from overreacting and damaging healthy tissue, but cancer hijacks this safety mechanism to protect itself. When cancer cells flip these molecular switches, they effectively paralyze nearby immune cells that would otherwise attack them.

Checkpoint inhibitor drugs—such as pembrolizumab (Keytruda) or ipilimumab (Yervoy)—work by blocking these inhibitory signals. These antibody drugs bind to either the checkpoint proteins on T cells or their partners on cancer cells, preventing the "off" signal from being transmitted. With the brakes released, T cells remain active and can resume their cancer-fighting duties.

This approach has transformed treatment for cancers like melanoma, lung cancer, and bladder cancer, where checkpoint inhibitors have produced durable responses in patients who previously had few options. However, removing these brakes can sometimes cause the immune system to attack healthy organs, leading to side effects like colitis or hepatitis that require careful medical management.

Once immune cells recognize cancer and have their brakes released, they need to be activated and expanded into sufficient numbers to mount an effective attack. This activation happens when T cells receive multiple signals: first, their receptors bind to cancer antigens, and second, they receive co-stimulatory signals from other immune cells or from therapies like cytokines (immune-signaling proteins such as interleukin-2 or interferon). Think of it like starting a car—you need both the key in the ignition and your foot on the accelerator.

Some immunotherapies directly provide these activation signals. Cytokine therapies flood the system with immune-stimulating proteins that tell T cells and natural killer cells to multiply and become more aggressive. Other treatments, like BiTE antibodies (bispecific T-cell engagers), physically link T cells to cancer cells, forcing close contact that triggers T cell activation. CAR-T cell therapies come pre-activated and are designed to multiply rapidly once they encounter their target antigen in the patient's body.

The activation phase transforms small populations of cancer-specific immune cells into armies numbering in the millions or billions. This massive expansion is essential because a single tumor can contain billions of cancer cells, and the immune system needs overwhelming force to eliminate them. However, this rapid proliferation requires careful monitoring, as the sudden release of cytokines from activated immune cells can sometimes cause dangerous inflammatory responses like cytokine release syndrome.

Once activated T cells reach cancer cells, they unleash a sophisticated arsenal of cell-killing mechanisms. Cytotoxic T cells release perforin, a protein that punches holes in the cancer cell's membrane, followed by granzymes—enzymes that pour through these holes and trigger the cancer cell's self-destruct program (apoptosis). This process is remarkably targeted: the T cell forms a tight seal with the cancer cell, creating a confined space where these toxic proteins destroy only the intended target without harming surrounding healthy tissue.

Natural killer (NK) cells provide a complementary attack strategy, releasing similar toxic granules but also detecting cancer cells that try to evade T cells by hiding their surface markers. Some immunotherapies enhance this killing efficiency: CAR-T cells are engineered to bind more tightly to cancer cells and release killing molecules more effectively, while antibody therapies like rituximab can tag cancer cells for destruction by marking them for attack by multiple immune cell types (a process called antibody-dependent cellular cytotoxicity).

The attack isn't instantaneous—cancer cells must be systematically hunted and killed throughout the body. Solid tumors present additional challenges because they create physical barriers and hostile environments with low oxygen and immunosuppressive signals that can dampen the attack. This is why combination approaches that both release checkpoints and enhance killing ability often work better than single-mechanism therapies.

Perhaps the most remarkable feature of immunotherapy is its potential to create lasting protection through immunological memory. After successfully attacking cancer, some T cells transform into memory T cells—long-lived sentinels that circulate through the body for years or even decades. These cells retain their training, remaining capable of quickly recognizing and responding if cancer cells reappear. This is fundamentally different from chemotherapy or radiation, which stop working once treatment ends.

When memory T cells encounter their target cancer antigens again, they respond far more rapidly and forcefully than during the initial response, multiplying within hours and immediately beginning to attack. This swift secondary response can eliminate small numbers of returning cancer cells before they grow into detectable tumors. Clinical data shows that patients who achieve complete responses with checkpoint inhibitors often maintain cancer-free status for years, even after stopping treatment—evidence that immunological memory continues working.

This memory function explains why immunotherapy can produce the distinctive "tail of the curve" seen in survival graphs for certain cancers: while not all patients respond initially, those who do often experience remarkably durable benefits. However, cancer can sometimes evolve to evade even memory responses by losing the antigens that immune cells recognize, which is why ongoing research focuses on targeting multiple cancer markers simultaneously and understanding how to maintain robust memory populations long-term.